ecrin-mdr-crcClinical2014Stage IVA Colorectal Cancer AJCC v7Solid NeoplasmStage IVB Colorectal Cancer AJCC v7Recurrent Colorectal CarcinomaStage IIIC Colorectal Cancer AJCC v7Stage IIIB Colorectal Cancer AJCC v7Colorectal NeoplasmsStage IIIA Colorectal Cancer AJCC v7Stage Iva Colorectal Cancer Ajcc V7Solid NeoplasmStage Ivb Colorectal Cancer Ajcc V7Recurrent Colorectal CarcinomaColorectal NeoplasmsStage Iiic Colorectal Cancer Ajcc V7Stage Iiib Colorectal Cancer Ajcc V7Stage Iiia Colorectal Cancer Ajcc V7Interventionalhttps://newmdr.ecrin.org/Study/2170414CanadaUnited States8CyclosporinsCyclosporineECRIN MDRActive, not recruitingfalseSelumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal CancerThis phase I/Ib trial studies the side effects and best dose of selumetinib when given together with cyclosporine in treating patients with solid tumors or colorectal cancer that have spread to other places in the body and cannot be cured or controlled with treatment. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as cyclosporine, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Giving selumetinib and cyclosporine may be a better treatment for solid tumors or colorectal cancer.2014-08-152170414NCT02188264